Comparative Pharmacology
Head-to-head clinical analysis: DIAL versus PRISMASOL BK 0 0 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAL versus PRISMASOL BK 0 0 IN PLASTIC CONTAINER.
DIAL vs PRISMASOL BK 0/0 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine; potentiates GABA-A receptor activity, enhancing chloride ion influx and neuronal hyperpolarization.
Prismasol BK 0/0 is a sterile, nonpyrogenic bicarbonate-buffered replacement solution for continuous renal replacement therapy (CRRT). It acts as an electrolyte and buffer replacement to correct acid-base disturbances and maintain fluid balance during hemofiltration, with no pharmacologic active drug component.
Intravenous: 10-20 mg initially, followed by 5-10 mg every 2-4 hours as needed; maximum cumulative dose 40 mg.
Administered as a continuous infusion at rates typically between 1000-4000 mL/hour depending on the desired effluent flow rate, patient fluid balance, and metabolic requirements. The solution is used as dialysate (hemodiafiltration) or replacement fluid (hemofiltration). Must be prescribed and administered under physician supervision using intravenous infusion via a dialyzer or hemofilter.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Not applicable; PRISMASOL is a dialysate solution, not a drug with systemic absorption; components are removed by dialysis.
Primarily renal excretion of unchanged drug (60-70%) and minor fecal elimination (<10%).
Renal (80-100% in urine as unabsorbed, not metabolized); minimal biliary/fecal.
Category C
Category C
Dialysis Solution
Dialysis Solution